180 Participants Needed

Doppler Probe Monitoring for Bleeding after Polyp Removal

Recruiting at 5 trial locations
DM
Overseen ByDennis M Jensen, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: VA Office of Research and Development
Must be taking: Anti-coagulants, Anti-platelets
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new method to prevent bleeding after colon polyp removal. It compares the use of a Doppler Endoscopic Probe (DEP), which checks and treats blood flow as needed, to standard procedures following medical guidelines. Candidates may be suitable if they take blood-thinning medications or have large polyps requiring removal. Participants should already plan to undergo a colonoscopy for screening, polyp detection, or abdominal pain evaluation. The trial aims to determine if the new method reduces bleeding risk more effectively than current practices. As an unphased trial, it offers participants the chance to contribute to innovative research that could enhance future medical procedures.

Do I need to stop my current medications for the trial?

The trial does not specify if you need to stop your current medications. However, it seems that participants are required to be on anti-coagulants or anti-platelet drugs, or have a specific condition related to polyp size, so you may need to continue your current medication if it falls into these categories.

What prior data suggests that the Doppler Endoscopic Probe is safe for monitoring bleeding after polyp removal?

Research has shown that using a Doppler endoscopic probe (DEP) is safe and straightforward. Studies have demonstrated that DEP can detect blood flow in the area where a polyp was removed, allowing doctors to assess bleeding risk. A recent study found that DEP use led to fewer bleeding problems compared to standard methods. Patients tolerated it well, with no major safety concerns reported.

In simpler terms, DEP appears to be a safe way to check blood flow after polyp removal. It helps doctors act quickly if needed, potentially reducing the risk of bleeding.12345

Why are researchers excited about this trial?

Researchers are excited about the Doppler Endoscopic Probe technique because it offers a new way to monitor and potentially prevent bleeding after polyp removal, which is something standard endoscopy doesn't currently address directly. Unlike traditional approaches that rely on standard post-procedural guidelines for managing bleeding risks, the Doppler probe can detect arterial blood flow at the site of polyp removal. If blood flow is detected, immediate treatment options like hemoclipping or electrocoagulation can be applied to stop the bleeding. This proactive approach could lead to more effective management of post-polypectomy complications, potentially reducing the risk of bleeding and improving patient outcomes.

What evidence suggests that the Doppler Endoscopic Probe is effective for preventing delayed bleeding after polyp removal?

In this trial, participants will be assigned to different treatment arms to evaluate the effectiveness of using a Doppler Endoscopic Probe (DEP) for monitoring bleeding after polyp removal. Research has shown that a DEP can help identify and stop bleeding after colon polyp removal. In the Doppler treatment arm, checking blood flow with the DEP resulted in fewer cases of delayed bleeding compared to the standard endoscopy arm. The DEP detects blood flow in arteries, allowing doctors to stop it early and reduce the risk of bleeding. This method has proven safe and effective in managing bleeding without causing additional problems. Overall, DEP offers a promising way to improve outcomes for patients at high risk of bleeding after polyp removal.23567

Who Is on the Research Team?

DM

Dennis M Jensen, MD

Principal Investigator

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Are You a Good Fit for This Trial?

This trial is for ambulatory patients aged 35 or older undergoing colonoscopy due to various reasons, including screening for cancer or polyps, abdominal pain, or bowel habit changes. Participants must be on anticoagulants like Warfarin or antiplatelet drugs such as aspirin and have a post-polypectomy induced ulcer (PPIU) of specific sizes. Those with bleeding disorders, inflammatory bowel diseases, unwillingness to consent or follow up are excluded.

Inclusion Criteria

I am 35 or older and can walk on my own, going for a planned health check.
I am being checked for stomach pain, changes in how often I go to the bathroom, or need a big polyp removed.
I am advised to take blood thinners or anti-platelet drugs due to my PPIU measurement.
See 2 more

Exclusion Criteria

I have ongoing rectal bleeding due to a long-term condition like hemorrhoids.
I have a bleeding disorder that causes me to bleed a lot after surgery or certain medical procedures.
I have a condition causing unexplained colon inflammation and frequent rectal bleeding.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Participants undergo colonoscopy with either Doppler endoscopic probe (DEP) treatment or standard endoscopy

1 day
1 visit (in-person)

Follow-up

Participants are monitored for bleeding, complications, or unscheduled visits for healthcare after polypectomies

4 weeks
3 visits (in-person) at 7, 14, and 30 days

What Are the Treatments Tested in This Trial?

Interventions

  • Doppler Endoscopic Probe
Trial Overview The study tests if using a Doppler Endoscopic Probe (DEP) to detect arterial blood flow and treat PPIUs can reduce delayed hemorrhage compared to standard medical guidelines alone. It's a randomized controlled trial focusing on high-risk patients who've had benign colon polyps removed and are at risk of post-procedure bleeding.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Standard endoscopy (not experimental)Experimental Treatment1 Intervention
Group II: Doppler treatment (experimental)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials
1,691
Recruited
3,759,000+

Kaiser Permanente

Collaborator

Trials
563
Recruited
27,400,000+

Kaiser Permanente Bellflower Medical Offices

Collaborator

Trials
2
Recruited
420+

University of California, Los Angeles

Collaborator

Trials
1,594
Recruited
10,430,000+

UCLA Health - Santa Monica Medical Center

Collaborator

Trials
2
Recruited
380+

Published Research Related to This Trial

In a preliminary study of 12 patients, the use of Doppler probe ultrasonography (DOP) after endoscopic submucosal dissection (ESD) successfully detected 20 previously invisible vessels, leading to additional coagulation without any cases of post-ESD rebleeding.
The DOP method proved to be safe and feasible, with no adverse events reported, suggesting it could be an effective tool for reducing the risk of rebleeding in patients undergoing ESD for early gastric cancer.
Endoscopic Doppler probe ultrasonography for detecting blood flow at post-endoscopic submucosal dissection ulcers of the stomach.Shiratori, Y., Ikeya, T., Oguri, N., et al.[2020]
In a study of 62 patients with peptic ulcer bleeding, second-look endoscopy using Doppler endoscopic probes (DEPs) showed a low rebleeding rate of 3%, suggesting it is a safe option for high-risk patients.
While DEP evaluation during second-look endoscopy did not significantly improve outcomes compared to standard treatment, it may still be beneficial for selected patients at risk of rebleeding.
Doppler-Guided Second-Look Endoscopy in Peptic Ulcer Bleeding: A Randomised Controlled Trial.Nielsen, MM., Schaffalitzky de Muckadell, OB., Laursen, SB.[2023]
The Doppler probe method (DOP) used after gastric endoscopic submucosal dissection (ESD) showed a trend towards lower rates of delayed bleeding (2.0% vs. 8.6%) and readmissions due to bleeding compared to standard methods, suggesting it may enhance safety in post-ESD care.
No adverse events were reported with the DOP method, indicating it is a safe intervention; however, further prospective studies are needed to confirm its efficacy in reducing delayed bleeding.
Doppler probe method to reduce delayed bleeding after endoscopic submucosal dissection in the stomach: a propensity-score matched study (with video).Shiratori, Y., Ikeya, T., Yamamoto, K., et al.[2023]

Citations

Endoscopic management of delayed bleeding after ...Delayed PPB (DPPB) typically occurs 2–7 days following polypectomy and its incidence is commonly reported to be 0.2%–2.2% [4, 5]. Several ...
Endoscopic Management of Post-Polypectomy BleedingA recent study [57] proposed the use of a Doppler endoscopic probe to detect superficial (<4 mm) arterial blood flow in the post-polypectomy ...
Clinical outcome of endoscopic management in delayed ...All 15 patients with recurrent bleeding were managed successfully without adverse events by repeat endoscopic intervention and none of the patients with ...
S767 Doppler Endoscopic Probe Blood Flow Monitoring ...DEP monitoring of arterial blood flow & guided treatment resulted in significantly lower rates of DPPIUH than standard treatment; was easy & safe.
Postpolypectomy lower GI bleeding: Descriptive analysisDoppler Endoscopic Probe Monitoring of Blood Flow Improves Risk Stratification and Outcomes of Patients With Severe Nonvariceal Upper Gastrointestinal ...
Endoscopic Management of Post-Polypectomy BleedingA recent study [57] proposed the use of a Doppler endoscopic probe to detect superficial (<4 mm) arterial blood flow in the post-polypectomy mucosal defect ...
Comprehensive review of outcomes of endoscopic ...BAE is indicated when the bleeding source has been identified by capsule endoscopy. Treatment success was reported to be 43% to 84%. However, a ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security